CORAL GABLES, Fla., Aug. 25 /PRNewswire/ -- Stiefel Laboratories, the
world's largest independent dermatology company, today announced that its
European affiliate, Stiefel Laboratories (Ireland) Ltd., has signed an
agreement to license the company's Sebiprox(R) dandruff shampoo to Grupo
Ferrer International S.A.
Sold by Stiefel under various brand names in Spain, France, Germany, Italy
and Morocco as a treatment for dandruff and other forms of seborrheic
dermatitis of the scalp, Sebiprox is the only anti-fungal dandruff shampoo
that is reimbursable under most major insurance plans in Spain.
The product, whose active ingredient is ciclopirox olamine, will be
manufactured and supplied to Ferrer by Stiefel's manufacturing facility in
Ireland. Ferrer will re-brand and sell the shampoo as part of its popular
Ciclochem(R) line of anti-fungal skin and hair care products. Stiefel will
continue to market the product to its core dermatologist customers under the
Sebiprox name in Spain and throughout its other territories.
The agreement, which covers an initial, renewable multi-year period and
extends throughout all of Spain, opens the door for Ferrer to expand the
distribution of Sebiprox beyond dermatologists to general practitioners and
other medical professionals.
According to Stiefel's Chairman, CEO & President, Charles W. Stiefel, "We
are very excited to further our relationship with Ferrer and are confident
that this agreement will prove to be beneficial not only for both companies,
but also for those who suffer from dandruff and seborrheic dermatitis. This
agreement exemplifies Stiefel's desire to partner with other companies in
order to expand our coverage and bring our innovative products to those
patients who need them."
Ciclopirox olamine is a broad spectrum anti-fungal and anti-inflammatory
agent used to treat a variety of fungus and yeast skin infections, including
seborrheic dermatitis of the scalp. Seborrheic dermatitis is believed to be
caused by a reaction to yeast organisms belonging to the Malassezia species.
Seborrheic dermatitis is a very common condition that causes scaling and
sometimes a red itchy rash of the scalp, eyebrows, face and/or chest.
The condition may appear gradually or suddenly at any age, usually after
puberty, and can last for many years, often getting better or worse without
any apparent reason. Although there is no permanent cure for the disease, it
is usually controlled by one or more treatments that include topical agents
and/or therapeutic shampoos.
Stiefel actively pursues acquisition opportunities and strategic alliances
worldwide and welcomes collaborative ventures typified by the agreement
announced today. In addition to license agreements and acquisitions, Stiefel
generates new products and technologies through its world-renowned research
and development group, which operates out of facilities on three continents,
including the southern hemisphere's largest dermatological research facility
located near Sao Paulo, Brazil.
About Stiefel Laboratories, Inc.
Founded in 1847, Stiefel Laboratories is the world's largest independent
pharmaceutical company specialized in dermatology. Its wholly owned global
network is comprised of more than 30 subsidiaries, including manufacturing
plants in six countries and R&D facilities on three continents. Stiefel
supplements its R&D by aggressively seeking acquisitions of dermatological
product lines and companies around the world. To learn more about Stiefel,
SOURCE Stiefel Laboratories, Inc.